Answers are grounded in this paper and cite their sources.
Sir, We present a case of a 52-year-old woman with RA who developed severe drug-induced hypereosinophilia with gastrointestinal involvement as a consequence of tocilizumab infusion. Her RA was diagnosed in 2011 with active synovitis, erosions on MRI of hand and wrist and histology of a lump removed from her face consistent with a rheumatoid nodule. Laboratory tests revealed negative RF, ACPA, ANA and ANCA. After intolerance to and/or failure of plaquenil, MTX, SSZ and LEF, she was initiated on biologic therapy 2 years after her diagnosis. Adalimumab was initiated and after 6 months was switched to abatacept due to secondary treatment failure. Within 4 months, abatacept was switched to tocilizumab due to primary treatment failure. Her eosinophil count throughout her disease course prior to commencement of tocilizumab therapy was within the normal range [0.1 × 109/l (normal range <0.4 × 109/l)]. By the second tocilizumab infusion, her RA was in remission. Full blood count revealed a new mild eosinophilia with eosinophil count of 1.9 × 109/l. After the third infusion, the eosinophil count had risen to 7.0 × 109/l. She subsequently developed severe epigastric pain (14 weeks after commencement of tocilizumab) and presented to the emergency department. On admission, her eosinophil count was 8.8 × 109/l. Figure 1 outlines her eosinophil count before and after admission. There had been no change in medication. A blood film revealed normal morphology of the peripheral eosinophils, with no dysplastic features in any of the cell lines. There were no other elevated blood counts. Investigations were performed to exclude other causes of hypereosinophilia, which include neoplastic, infectious or other autoimmune processes. All investigations were normal, including Strongyloides serology, faecal ova, cysts and parasites, ANCA, tryptase, serum protein electrophoresis, CT of the chest, abdomen and pelvis, bone marrow biopsy and trephine. She was treated empirically with ivermectin for Strongyloides despite negative serology. Her eosinophilia persisted. Other investigations for her severe epigastric pain, including ECG and cardiac enzymes, were normal. Endoscopy revealed a normal-looking oesophagus, stomach and duodenum, but histology revealed an eosinophilic infiltrate in the oesophagus, gastric antrum and duodenum, with eosinophilic microabscesses in the basal epithelial layers and desquamation of the surface epithelial layers consistent with a drug-induced reaction. She was diagnosed with drug-induced hypereosinophilia with gastrointestinal involvement. The tocilizumab infusions were ceased, with resolution of her peripheral eosinophilia over the following months (Fig. 1). No CSs were given during this time period because the patient had not tolerated CSs in the past. Subsequently, her joint symptoms worsened and she was managed with analgesic medications alone. Five months after cessation of tocilizumab, repeat endoscopy showed complete resolution of the eosinophilic infiltrate. Her arthritis flared. She was initiated on another TNF inhibitor, but due to secondary failure transitioned to rituximab to good effect. Eosinophil count before, during and after cessation of tocilizumab To our knowledge, this is the first report of drug-induced hypereosinophilia related to tocilizumab therapy. Hypereosinophilia is defined as moderate to severe eosinophilia (≥1.5 × 109/l) with or without end-organ manifestations. Eosinophil-mediated organ injury is caused by local inflammation driven by toxic granule protein mediators released locally into the tissue by eosinophil infiltration. All organ systems may be affected, with dermatological involvement being the most common, followed by pulmonary, gastrointestinal and cardiac involvement [1]. Underlying aetiologies that need to be considered when hypereosinophilia occurs are neoplastic (chronic eosinophilic leukaemia), infective (commonly parasitic) and autoimmune processes (ANCA vasculitis). Idiopathic hypereosinophilia occurs in more than 50% of cases where, despite extensive investigation, an underlying aetiology is not found. Drug-induced eosinophilia is a diagnosis of exclusion where a temporal relationship exists between drug initiation, development of eosinophilia and eosinophilia resolution with drug cessation. Certain rheumatological medications, such as SSZ, allopurinol and ciclosporin, are known to be associated with drug reaction with eosinophilia. Limited case reports exist involving infliximab and adalimumab in both RA and PsA patients, highlighting an association between anti-TNF-α therapy and hypereosinophilia [2, 3]. It has been postulated that this reaction occurs as a result of an exaggerated Th2 response to anti-TNF-α therapy. Etanercept and adalimumab have been reported to cause an eosinophilic cellulitis (Wells’ syndrome) at the site of s.c. injection [4, 5], and certolizumab is reported to cause peripheral eosinophilia in 10 in 1000 patients [3]. Hypereosinophilia in this case was associated with an eosinophilic infiltrate into the epithelial layer of the gastrointestinal tract, resulting in the patient experiencing severe epigastric pain that required hospitalization. In this case, the eosinophil count rose steadily over the first 3 months (Fig. 1) and was already significantly raised 1 month after the first infusion. We would therefore recommend that a full blood count be performed monthly for the first 3 months. If the eosinophil count is seen to rise, then we would recommend withdrawal of further treatment with tocilizimab in order to prevent end-organ damage. Rheumatology key message Early detection of hypereosinophilia with tocilizumab treatment in RA may prevent end-organ damage. Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript. Disclosure statement: The authors have declared no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Morrisroe et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: